MarketReserchReports.biz
has recently announced the addition of a market study “
PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma -
Global Drug Forecast and Market Analysis to 2024 ”
Gastric
and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the
majority of gastric cancer cases worldwide. It is the fifth most
diagnosed cancer globally, and the third most common cause of cancer
death in the world. The major treatments for G/GEJAC are
chemotherapy-based, but targeted therapies such as HER2 and
angiogenesis inhibitors have been approved and are being added to
chemotherapy regimens since 2010 and 2014, respectively.
GlobalData
estimates the 2014 sales for G/GEJAC at approximately $1.13 billion
across the 8MM covered in this report. The market is expected to
reach $4.39 billion in 2024 at a CAGR of 14.6%. This growth will be
mainly driven by the approval and uptake of premium-priced products,
such as Eli Lillys Cyramza (ramucirumab)
and PD-1-targeting mAbs, Merck & Co.s Keytruda (pembrolizumab)
and BMS Opdivo (nivolumab). GlobalData expects, by the end of the
forecast period, Cyramza to dominate the G/GEJAC market with an
overall 37% share of the G/GEJAC market.
The
G/GEJAC pipeline is strong; however, GlobalData expects many of these
drugs to launch only in Japan and China, limiting their outlook. For
the pipeline drugs that are in a global development. Roches Perjeta
(pertuzumab) and Merck & Co.s Keytruda are the most promising.
While the HER2-positive segment of the G/GEJAC will be dominated by
Roche over the forecast period, GlobalData projects there will be
opportunities for companies to develop novel therapeutics targeting
the HER2-negative first-line setting.
View
Report At http://www.marketresearchreports.biz/analysis/667480
Highlights
Key
Questions Answered
-
What will be the impact of the new anti-PD-1 inhibitors and their
projected label expansions on the G/GEJAC market sales? Given the
recent reports on clinical efficacy of these pipeline drugs, there is
a good deal of potential in the G/GEJAC space for anti-PD-1
inhibitors over the forecast period.
-
As the HER2-positive segment of the G/GEJAC market is dominated by
Roche, pharmaceutical companies aim to establish their foothold in
the underserved HER2-negative space. What R&D strategies are
being pursued by drug makers to stand out?
-
The development of drugs for G/GEJAC has been slow, especially after
the failure of Phase III trials of multiple pre-2014 pipeline agents.
Therefore, there are considerable high unmet needs within the
indication. What are the main unmet needs in this market? Will the
drugs under development fulfil the unmet needs of the G/GEJAC market?
Key
Findings
-
One of the main drivers of the enormous expansion of the G/GEJAC
market will be the launch of premium-priced metastatic therapies,
such as HER2-targeted therapy Perjeta, and anti-PD-1 immunotherapies
Keytruda and Opdivo. The uptake of recently-approved Cyramza and its
projected label expansion into the HER2-negative first-line setting
will also be key. These drugs will extend treatment duration and will
be added onto the current standard-of-care regimens.
-
Key patent expiry of Herceptin across the major markets and
subsequent biosimilar entries expected starting in 2017 represent a
major barrier of the growth of the G/GEJAC market. GlobalData expects
trastuzumab biosimilars to occupy a fifth of total molecule sales in
2024, the end of the forecast period.
-
Companies are focusing on the development of therapies for the
second-line treatment and for HER2-negative patients in the first
line, trying to avoid excessive competition with the current standard
of care.
-
One of the largest unmet needs is efficacious perioperative and
postoperative treatment options for resected patients to prevent
disease recurrence. Currently, no company-sponsored trials are planed
to address this unmet need.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/667480
Scope
-
Overview of G/GEJAC, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and disease management.
-
Annualized G/GEJAC therapeutics market revenue, cost of therapy per
patient, and treatment usage patterns in seven patient segments
(including adjuvant, HER2-positive and HER2-negative), forecast from
2014 to 2024.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and
implications for the G/GEJAC therapeutics market.
-
Pipeline analysis: comprehensive data assessing emerging trends and
mechanisms of action under development for different lines of
therapy. The most promising candidate in Phase III development is
profiled.
-
Analysis of the current and future market competition in the global
G/GEJAC therapeutics market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Reasons
to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline.
-
Develop business strategies by understanding the trends shaping and
driving the global G/GEJAC therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global G/GEJAC therapeutics market in the future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Table
of Contents
1
Table of Contents
1
Table of Contents 10
1.1
List of Tables 17
1.2
List of Figures 23
2
Introduction 26
2.1
Catalyst 26
2.2
Related Reports 27
2.3
Upcoming Related Reports 27
3
Disease Overview 28
3.1
Etiology and Pathophysiology 28
3.1.1
Etiology 28
3.1.2
Pathophysiology 28
3.1.3
Biomarkers/Targets of Interest 30
3.2
Staging 31
3.3
Symptoms 33
3.4
Prognosis 33
3.5
Quality of Life 34
4
Epidemiology 36
4.1
Disease Background 36
4.2
Risk Factors and Comorbidities 37
4.3
Global Trends 38
4.3.1
8MM, Incidence Trends 39
4.4
Forecast Methodology 41
4.4.1
Sources Used 47
4.4.2
Sources Not Used 55
4.4.3
Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric
Cancer - 8MM 56
4.4.4
Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases
of Gastric Cancer - 8MM 57
4.4.5
Forecast Assumptions and Methods, Gastric Cancer Clinical Stages at
Diagnosis - 8MM 58
4.4.6
Forecast Assumptions and Methods, Gastric Cancer Cellular Types - 8MM
59
4.4.7
Forecast Assumptions and Methods, HER2 Status - 8MM 61
4.4.8
Forecast Assumptions and Methods, Diagnosed Incident Cases of GEJ
Cancer - 8MM 62
4.4.9
Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric
Adenocarcinomas - 8MM 64
4.5
Epidemiological Forecast of Gastric Cancer (2014-2024) 64
4.5.1
Diagnosed Incident Cases of Gastric Cancer 64
4.5.2
Age-Specific Diagnosed Incident Cases of Gastric Cancer 66
4.5.3
Sex-Specific Diagnosed Incident Cases of Gastric Cancer 67
4.5.4
Age-Standardized Diagnosed Incidence of Gastric Cancer 69
4.5.5
Percentage Distribution of Diagnosed Incident Cases of Gastric
Cancer, by Stage at Diagnosis 70
4.5.6
Percentage Distribution of Diagnosed Incident Cases of Gastric
Cancer, by Cellular Type 71
4.5.7
Diagnosed Incident Cases of Gastric Cancer by HER2 Status 72
4.5.8
Diagnosed Incident Cases of GEJ Cancer 74
4.5.9
Five-Year Diagnosed Prevalent Cases of Gastric Cancer 76
4.6
Discussion 77
4.6.1
Epidemiological Forecast Insight 77
4.6.2
Limitations of the Analysis 78
4.6.3
Strengths of the Analysis 79
5
Disease Management 80
5.1
Diagnosis and Treatment Overview 80
5.1.1
Screening 80
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment